Goldman Sachs Reiterates Conviction Buy on Quest Diagnostics (DGX)

Goldman Sachs reiterated its Conviction Buy rating on Quest Diagnostics (NYSE: DGX) and price target of $79.00.

Analyst Isaac Ro commented, "We reiterate our CL-Buy on Quest Diagnostics (DGX) heading into 2015. Labs and Services was the worstperforming coverage group in our Goldman Sachs Americas Healthcare coverage in 2014. While we acknowledge utilization trends have only recently signaled an improvement, we believe this underperformance sets up well for 2015 as cyclical and secular tailwinds emerge. Below we re-highlight the primary drivers of our Buy thesis."

For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.

Shares of Quest Diagnostics closed at $63.78 yesterday.

You May Also Be Interested In

• Rubrik IPO: 5 key things to know
• Needham Reiterates Buy Rating on Amazon.com (AMZN), Raises Estimates
• Hertz Global (HTZ) PT Lowered to $6 at Deutsche Bank